Innate Pharma Stock Price Prediction
| IPHA Stock | USD 2.42 0.02 0.82% |
Oversold Vs Overbought
51
Oversold | Overbought |
Innate Pharma stock price prediction is an act of determining the future value of Innate Pharma shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Innate Pharma's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Innate Pharma and does not consider all of the tangible or intangible factors available from Innate Pharma's fundamental data. We analyze noise-free headlines and recent hype associated with Innate Pharma, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting Innate Pharma's stock price prediction:Quarterly Earnings Growth (0.75) | Wall Street Target Price 7.39 | Quarterly Revenue Growth 0.774 |
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Innate Pharma based on different types of headlines from major news networks to social media. The Innate stock price prediction module provides an analysis of price elasticity to changes in media outlook on Innate Pharma over a specific investment horizon. Using Innate Pharma hype-based prediction, you can estimate the value of Innate Pharma from the perspective of Innate Pharma response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in Innate Pharma. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Innate Pharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Innate because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Innate Pharma after-hype prediction price | USD 2.42 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Innate |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Innate Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Innate Pharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Innate Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Innate Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Innate Pharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Innate Pharma Estimiated After-Hype Price Volatility
In the context of predicting Innate Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Innate Pharma's historical news coverage. Innate Pharma's after-hype downside and upside margins for the prediction period are 0.12 and 6.98, respectively. We have considered Innate Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Innate Pharma is risky at this time. Analysis and calculation of next after-hype price of Innate Pharma is based on 3 months time horizon.
Innate Pharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Innate Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Innate Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Innate Pharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.00 | 4.56 | 0.00 | 0.00 | 8 Events / Month | 9 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
2.42 | 2.42 | 0.00 |
|
Innate Pharma Hype Timeline
Innate Pharma is currently traded for 2.42. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Innate is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at 0.0%. %. The volatility of related hype on Innate Pharma is about 136800.0%, with the expected price after the next announcement by competition of 2.42. The book value of the company was currently reported as 0.64. The company recorded a loss per share of 0.1. Innate Pharma had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in about 8 days. Check out Innate Pharma Basic Forecasting Models to cross-verify your projections.Innate Pharma Related Hype Analysis
Having access to credible news sources related to Innate Pharma's direct competition is more important than ever and may enhance your ability to predict Innate Pharma's future price movements. Getting to know how Innate Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Innate Pharma may potentially react to the hype associated with one of its peers.
Innate Pharma Additional Predictive Modules
Most predictive techniques to examine Innate price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Innate using various technical indicators. When you analyze Innate charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Innate Pharma Predictive Indicators
The successful prediction of Innate Pharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Innate Pharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Innate Pharma based on analysis of Innate Pharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Innate Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Innate Pharma's related companies. | 2023 | 2024 (projected) | Dividend Yield | 0.0039 | 0.003705 | Price To Sales Ratio | 3.93 | 3.73 |
Story Coverage note for Innate Pharma
The number of cover stories for Innate Pharma depends on current market conditions and Innate Pharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Innate Pharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Innate Pharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
View All Premium Stories
Innate Pharma Short Properties
Innate Pharma's future price predictability will typically decrease when Innate Pharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Innate Pharma often depends not only on the future outlook of the potential Innate Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Innate Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 80.5 M | |
| Cash And Short Term Investments | 92.5 M |
Check out Innate Pharma Basic Forecasting Models to cross-verify your projections. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.Note that the Innate Pharma information on this page should be used as a complementary analysis to other Innate Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for Innate Stock analysis
When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Innate Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.75) | Earnings Share (0.10) | Revenue Per Share 0.766 | Quarterly Revenue Growth 0.774 | Return On Assets (0.04) |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.